Not sure what happens to #Bardoxolone in #Alport
#NephJC summary: http://www.nephjc.com/news/bardoxolone

FDA rejection https://www.hcplive.com/view/fda-rejects-bardoxolone-methyl-chronic-kidney-disease

6/6

A downstream effect is that this has lead to a premature halting of the FALCON trial of #Bardoxolone in #ADPKD N = 809 https://clinicaltrials.gov/ct2/show/NCT03918447

via this https://pkdcure.org/why-did-the-falcon-clinical-trial-end/

I guess the molecule is mostly dead?

5/

Things getting weird with #Bardoxolone (who would have thunk!)

Remember bard is the nrf-2 activator and has been reported to *increase* GFR. This molecule bombed with the Ph 3 BEACON trial where it caused *more* HF and MACE https://www.nejm.org/doi/full/10.1056/nejmoa1306033

Does #Bardoxolone do anything in #Alport beyond make the #GFR number go up?

Read as Jamie Willows and @Priti899 eviscerate the #CARDINAL trial for #nephJC

http://www.nephjc.com/news/bardoxolone

Discussion this week